文献速递血液净化与透析

静脉铁剂剂量与血液透析患者感染风险:PIVOTAL试验预设二次分析

Intravenous Iron Dosing and Infection Risk in Patients on Hemodialysis: A Prespecified Secondary Analysis of the PIVOTAL Trial.
PubMed 文献 · J Am Soc Nephrol · 2020-04-06

PIVOTAL试验将2141例维持性血液透析的ESKD患者随机分配至高剂量或低剂量静脉铁剂组,感染率为预设二次分析。结果显示两组全因感染、感染住院及感染死亡无显著差异;近期感染与首次心血管事件风险显著相关。

要点

  • 高剂量与低剂量静脉铁剂组感染率无显著差异。
  • 导管透析患者感染发生率高于动静脉瘘患者。
  • 近期感染与首次心血管事件风险显著相关。

核心结论

  • 高剂量与低剂量静脉铁剂组的感染率相同。
  • 首次心血管事件风险与近期感染强烈相关。

研究设计与样本

  • PIVOTAL试验的预设二次分析,纳入2141例维持性血液透析的ESKD患者,随机分为高剂量或低剂量静脉铁剂组。

主要发现

  • 高剂量组与低剂量组全因感染事件率分别为46.5%与45.5%,发病率分别为63.3与69.4每100患者年,无显著差异。
  • 感染住院率在高剂量组与低剂量组分别为29.6%与29.3%,无差异。
  • 与动静脉瘘透析患者相比,导管透析患者任何感染、感染住院或致命感染的发生率更高,但静脉铁剂剂量对这些结局无影响。
  • 首次心血管事件风险与过去30天内任何感染显著相关。

关键数值与推荐

  • 全因感染事件率:高剂量组46.5%,低剂量组45.5%。
  • 感染发病率:高剂量组63.3每100患者年,低剂量组69.4每100患者年。
  • 感染住院率:高剂量组29.6%,低剂量组29.3%。

临床怎么用

  • 维持性血液透析患者使用高剂量静脉铁剂未增加感染风险。
  • 导管透析患者感染风险较高,应关注感染预防。
  • 近期感染患者需警惕心血管事件风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Experimental and observational studies have raised concerns that giving intravenous (IV) iron to patients, such as individuals receiving maintenance hemodialysis, might increase the risk of infections. The Proactive IV Iron Therapy in Haemodialysis Patients (PIVOTAL) trial randomized 2141 patients undergoing maintenance hemodialysis for ESKD to a high-dose or a low-dose IV iron regimen, with a primary composite outcome of all-cause death, heart attack, stroke, or hospitalization for heart failure. Comparison of infection rates between the two groups was a prespecified secondary analysis. METHODS: Secondary end points included any infection, hospitalization for infection, and death from infection; we calculated cumulative event rates for these end points. We also interrogated the interaction between iron dose and vascular access (fistula versus catheter). RESULTS: We found no significant difference between the high-dose IV iron group compared with the lose-dose group in event rates for all infections (46.5% versus 45.5%, respectively, which represented incidences of 63.3 versus 69.4 per 100 patient years, respectively); rates of hospitalization for infection (29.6% versus 29.3%, respectively) also did not differ. We did find a significant association between risk of a first cardiovascular event and any infection in the previous 30 days. Compared with patients undergoing dialysis with an arteriovenous fistula, those doing so via a catheter had a higher incidence of having any infection, hospitalization for infection, or fatal infection, but IV iron dosing had no effect on these outcomes. CONCLUSIONS: The high-dose and low-dose IV iron groups exhibited identical infection rates. Risk of a first cardiovascular event strongly associated with a recent infection.

来源:J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. Macdougall IC, Bhandari S, White C, et al. Intravenous Iron Dosing and Infection Risk in Patients on Hemodialysis: A Prespecified Secondary Analysis of the PIVOTAL Trial. J Am Soc Nephrol. 2020. PMID: 32253271. doi:10.1681/ASN.2019090972

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。